Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

W. Willenbacher · SciRah

Researcher profile · Semantic Scholar

W. Willenbacher

Share profile

W. Willenbacher — researcher profile on SciRah

h-index: 29
Works: 191
Citations: 4,625

Most-cited papers

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
N. Raje, E. Terpos, W. Willenbacher, K. Shimizu +9 more
2018The Lancet Oncology397 citations
Semantic Scholar
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study.
R. Ramchandren, E. Domingo-Domènech, A. Rueda, M. Trněný +16 more
2019Journal of Clinical Oncology212 citations Open access
Semantic Scholar
Inflammation-Induced Tryptophan Breakdown is Related With Anemia, Fatigue, and Depression in Cancer
L. Lanser, P. Kink, E. Egger, W. Willenbacher +3 more
2020Frontiers in Immunology149 citations Open access
Semantic Scholar
Curcumin: New Insights into an Ancient Ingredient against Cancer
E. Willenbacher, S. Khan, S. C. A. Mujica, D. Trapani +5 more
2019International Journal of Molecular Sciences141 citations Open access
Semantic Scholar
Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study
S. Ansell, P. Bröckelmann, G. von Keudell, Hun Lee +17 more
2023Blood Advances94 citations Open access
Semantic Scholar
Multiple Myeloma Treatment in Real‐world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study
M. Mohty, E. Terpos, M. Mateos, M. Cavo +28 more
2018Clinical Lymphoma, Myeloma & Leukemia72 citations Open access
Semantic Scholar
Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)
M. Rummel, Christian A. Lerchenmüller, M. Hensel, M. Goerner +14 more
2019Blood64 citations Open access
Semantic Scholar
A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.
B. Kiesewetter, E. Willenbacher, W. Willenbacher, A. Egle +7 more
2017Blood53 citations Open access
Semantic Scholar
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial.
S. Kreissl, H. Goergen, Ina Buehnen, C. Kobe +30 more
2021The Lancet Haematology49 citations Open access
Semantic Scholar
Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia
I. Dogliotti, C. Jiménez, M. Varettoni, D. Talaulikar +26 more
2022Leukemia48 citations Open access
Semantic Scholar
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia
R. Kreitman, P. Moreau, F. Ravandi, M. Hutchings +13 more
2022Blood47 citations Open access
Semantic Scholar
Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
P. Mondello, N. Steiner, W. Willenbacher, C. Cerchione +5 more
2018The Oncologist38 citations Open access
Semantic Scholar
Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review.
C. Buske, S. Sadullah, E. Kastritis, A. Tedeschi +10 more
2018The Lancet Haematology37 citations Open access
Semantic Scholar
Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL)
R. Kreitman, P. Moreau, M. Hutchings, A. Gazzah +13 more
2018Blood36 citations Open access
Semantic Scholar
The cancer patient’s perspective of COVID‐19‐induced distress—A cross‐sectional study and a longitudinal comparison of HRQOL assessed before and during the pandemic
K. Koinig, C. Arnold, J. Lehmann, J. Giesinger +7 more
2021Cancer Medicine31 citations Open access
Semantic Scholar
Recent Advances in Castleman Disease
C. Hoffmann, M. Hentrich, M. Tiemann, A. Rosenwald +3 more
2022Oncology Research and Treatment30 citations
Semantic Scholar
Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study
R. Ramchandren, M. Fanale, A. Rueda, P. Armand +11 more
201727 citations
Semantic Scholar
The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event
Maurus Locher, M. Steurer, Emina Jukic, M. Keller +12 more
2020American journal of hematology/oncology26 citations Open access
Semantic Scholar
Real‐world non‐interventional long‐term post‐authorisation safety study of ruxolitinib in myelofibrosis
F. Barraco, R. Greil, R. Herbrecht, B. Schmidt +9 more
2020British Journal of Haematology25 citations Open access
Semantic Scholar
Using the Computer-based Health Evaluation System (CHES) to Support Self-management of Symptoms and Functional Health: Evaluation of Hematological Patient Use of a Web-Based Patient Portal
J. Lehmann, Petra Buhl, J. Giesinger, L. Wintner +7 more
2020Journal of Medical Internet Research23 citations Open access
Semantic Scholar
Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
H. Ludwig, W. Poenisch, S. Knop, A. Egle +13 more
2019British Journal of Cancer21 citations Open access
Semantic Scholar
A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America
N. Raje, G. Roodman, W. Willenbacher, K. Shimizu +6 more
2018Journal of Medical Economics21 citations Open access
Semantic Scholar
NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY
S. Ansell, P. Bröckelmann, G. von Keudell, Hun Lee +16 more
2021Hematological Oncology20 citations Open access
Semantic Scholar
ABVD vs BEACOPP escalated in advanced‐stage Hodgkin’s lymphoma: Results from a multicenter European study
P. Mondello, C. Musolino, I. Dogliotti, J. Bohn +14 more
2020American journal of hematology/oncology19 citations Open access
Semantic Scholar
Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies
W. Willenbacher, A. Seeber, N. Steiner, E. Willenbacher +4 more
2018International Journal of Molecular Sciences19 citations Open access
Semantic Scholar
Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population
H. Ludwig, W. Pönisch, S. Knop, A. Egle +19 more
2019Leukemia and Lymphoma18 citations Open access
Semantic Scholar
Complementing clinical cancer registry data with patient reported outcomes: A feasibility study on routine electronic patient‐reported outcome assessment for the Austrian Myelome Registry
M. Sztankay, Lucia Neppl, L. Wintner, F. Loth +6 more
2019European Journal of Cancer Care17 citations Open access
Semantic Scholar
Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): Results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial).
M. Rummel, M. Koenigsmann, K. Chow, W. Knauf +16 more
201817 citations
Semantic Scholar
Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial
G. Nowakowski, W. Willenbacher, R. Greil, T. Larsen +16 more
2021International journal of hematology16 citations
Semantic Scholar
Impact of denosumab (DMB) compared with zoledronic acid (ZA) on renal function in the treatment of myeloma bone disease.
N. Raje, G. Roodman, W. Willenbacher, K. Shimizu +6 more
201715 citations
Semantic Scholar
Adherence to Patient-Reported Symptom Monitoring and Subsequent Clinical Interventions for Patients With Multiple Myeloma in Outpatient Care: Longitudinal Observational Study
J. Lehmann, K. D. de Ligt, S. Tipelius, J. Giesinger +8 more
2023Journal of Medical Internet Research14 citations Open access
Semantic Scholar
NIVOLUMAB PLUS DOXORUBICIN, VINBLASTINE AND DACARBAZINE FOR NEWLY DIAGNOSED ADVANCED‐STAGE CLASSICAL HODGKIN LYMPHOMA: CHECKMATE 205 COHORT D 2‐YEAR FOLLOW‐UP
S. Ansell, Radhakrishnan Ramchandren, Eva Domingo Domenech, A. Rueda +11 more
2019Hematological Oncology13 citations
Semantic Scholar
A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy
E. Terpos, A. Jamotte, A. Christodoulopoulou, M. Campioni +3 more
2019Journal of Medical Economics13 citations Open access
Semantic Scholar
SAFETY AND EFFICACY OF THE PD‐L1 INHIBITOR DURVALUMAB WITH R‐CHOP OR R2‐CHOP IN SUBJECTS WITH PREVIOUSLY UNTREATED, HIGH‐RISK DLBCL
G. Nowakowski, W. Willenbacher, R. Greil, T. S. Larsen +15 more
2019Hematological Oncology12 citations Open access
Semantic Scholar
Short overview on the current standard of treatment in newly diagnosed multiple myeloma
E. Willenbacher, A. Balog, W. Willenbacher
2018memo - Magazine of European Medical Oncology12 citations Open access
Semantic Scholar
Attrition Rates in Multiple Myeloma Treatment under Real World Conditions—An Analysis from the Austrian Myeloma Registry (AMR)
M. Benda, H. Ulmer, R. Weger, P. Reimann +11 more
2023Cancers11 citations Open access
Semantic Scholar
HL-398: Five-Year Overall Survival from the CheckMate 205 Study of Nivolumab for Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)
S. Ansell, P. Bröckelmann, G. von Keudell, Hun Lee +15 more
202111 citations
Semantic Scholar
Immune Activation and Anemia Are Associated with Decreased Quality of Life in Patients with Solid Tumors
P. Kink, E. Egger, L. Lanser, Michaela Klaunzner +6 more
2020Journal of Clinical Medicine11 citations Open access
Semantic Scholar
An International, Randomized, Double Blind Trial Comparing Denosumab With Zoledronic Acid (ZA) for the Treatment of Bone Disease in Patients (Pts) With Newly Diagnosed Multiple Myeloma
N. Raje, E. Terpos, W. Willenbacher, K. Shimizu +9 more
201711 citations
Semantic Scholar
The Agony of Choice—Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond
I. Strassl, M. Schreder, N. Steiner, J. Rudzki +7 more
2021Cancers10 citations Open access
Semantic Scholar
Visible and near-infrared hyperspectral imaging techniques allow the reliable quantification of prognostic markers in lymphomas: a pilot study using the Ki67 proliferation index as an example.
E. Willenbacher, A. Brunner, W. Willenbacher, B. Zelger +4 more
2020Experimental Hematology10 citations Open access
Semantic Scholar
Progression-Free Survival Subset Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study
E. Terpos, W. Willenbacher, K. Shimizu, R. García-Sanz +4 more
2018Blood10 citations
Semantic Scholar
Serologic Responses to COVID-19 Vaccines in Hematological Patients Are Predominantly Impaired in Lymphoid but not in Myeloid Malignancies
Verena Petzer, N. Steiner, O. Angelova-Unterberger, G. Hetzenauer +18 more
2022HemaSphere9 citations Open access
Semantic Scholar
Application of mid‐infrared microscopic imaging for the diagnosis and classification of human lymphomas
E. Willenbacher, A. Brunner, B. Zelger, S. Unterberger +4 more
2021Journal of Biophotonics9 citations Open access
Semantic Scholar
Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R2-CHOP in subjects with previously untreated, high-risk DLBCL.
G. Nowakowski, W. Willenbacher, R. Greil, T. Larsen +15 more
2019Journal of Clinical Oncology9 citations Open access
Semantic Scholar
Progression-Free Survival Analysis of Denosumab Vs Zoledronic Acid in Intent to Transplant Multiple Myeloma Patients Based on Treatment Regimen and Baseline Characteristics
E. Terpos, R. García-Sanz, K. Shimizu, W. Willenbacher +4 more
2019Blood9 citations Open access
Semantic Scholar
Comparing functional and genomic‐based precision medicine in blood cancer patients
L. Kazianka, A. Pichler, Christiane Agreiter, Johannes Rohrbeck +23 more
2025HemaSphere7 citations Open access
Semantic Scholar
Poor Mobilizers in Lymphoma but Not Myeloma Patients Had Significantly Poorer Progression-Free Survival after Autologous Stem Cell Transplantation: Results of a Large Retrospective, Single-Center Observational Study
N. Steiner, G. Göbel, Leonie Mauser, Lena Mühlnikel +11 more
2023Cancers7 citations Open access
Semantic Scholar
Amp(1q) and tetraploidy are commonly acquired chromosomal abnormalities in relapsed multiple myeloma
Maurus Locher, Emina Jukic, Verena Vogi, M. Keller +12 more
2022European Journal of Haematology6 citations Open access
Semantic Scholar
Digital PCR in bone marrow trephine biopsies is highly sensitive for MYD88L265P detection in lymphomas with plasmacytic/plasmacytoid differentiation
E. Willenbacher, W. Willenbacher, D. Wolf, B. Zelger +4 more
2019British Journal of Haematology6 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

E. Willenbacher×10
Invite
E. Willenbacher — researcher profile on SciRah
R. Greil×9
Invite
R. Greil — researcher profile on SciRah
E. Terpos×8
Invite
E. Terpos — researcher profile on SciRah
R. García-Sanz×8
Invite
R. García-Sanz — researcher profile on SciRah

×7

Invite

N. Steiner — researcher profile on SciRah

Invite

N. Raje — researcher profile on SciRah

Invite

K. Shimizu — researcher profile on SciRah

M. Provencio×6

Invite

M. Provencio — researcher profile on SciRah

Invite

R. Weger — researcher profile on SciRah

Invite

D. Wolf — researcher profile on SciRah

E. Gunsilius×6

Invite

E. Gunsilius — researcher profile on SciRah

Invite

M. Trněný — researcher profile on SciRah